Open AccessOnconephrology: Update in Anticancer Drug-Related Nephrotoxicity
Author(s) -
Clara García-Carro,
Juliana Draibe,
María José Soler
Publication year - 2022
Publication title -
the nephron journals/nephron journals
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 72
eISSN - 2235-3186
pISSN - 1660-8151
DOI - 10.1159/000525029
Subject(s) - medicine , nephrotoxicity , cancer , kidney cancer , immunotherapy , kidney disease , chemotherapy , drug , intensive care medicine , disease , acute kidney injury , oncology , nephrology , targeted therapy , toxicity , pharmacology
The relation that connects cancer and renal damage is bidirectional and this renal damage worsens quality of life and increases morbidity in high-complexity patients such as patients with cancer and kidney injury. Strikingly, in the last decade, the treatment of advanced cancer has clearly advanced in terms of new therapeutic strategies with the ability to transform the advanced metastatic cancer in a chronic condition. In this new era of cancer therapies, cancer treatment including conventional chemotherapy, targeted cancer agents and immunotherapies among others are significantly associated with kidney injury. Renal toxicity that is currently seen in onconephrology departments is in part related to the new therapies such as immunotherapy, and to the prolonged survival achieved at the expense of increasing therapy lines, and a combination of different drugs. In this review, we will discuss in a practical way, nephrotoxicity caused by the main oncospecific treatments such as classical chemotherapy agents, targeted therapies, and immunotherapy. In addition, strategies for prevention and management recommendations in patients with malignancies and kidney disease will also be addressed.